Loading stock analysis…
Evidence Synthesis
Last synthesized: 21 Oct 2026, 07:37
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
Infronicics Sees a Decline in Trading Activity, as Daily Volume Falls to 703 Shares.
The stock's price has also taken a hit, with a drop of 1.27% from the previous day's close of 20.5 INR.
In terms of profitability, the company's gross margin and marginal operating leverage remain unchanged at .
These metrics indicate a standard shift in the company's performance, with a decelerating trend in daily trading activity and a decline in the price.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 0 % | 0 | - |
| MARGINAL_OPERATING_LEVERAGE | 0 % | 0 | - |
| PRICE_CHANGE_PERCENT | -1.268 % | — | - |
| DAILY_VOLUME | 703 shares | 2,830 | ▼ |
| CLOSE_PRICE | 20.24 INR | 20.5 | ▼ |
Cite this
Source: Samhati evidence synthesis for INFRONICS (2026-10-21). Observation: Infronicics Sees a Decline in Trading Activity, as Daily Volume Falls to 703 Shares. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/infronics